Aignostics Launches HETA Clinical AI for Pathology Workflow

Aignostics, a Berlin-based AI company, announced the launch of HETA Clinical, a new family of pan-cancer AI products designed to accelerate pathology workflows and reduce failed molecular tests. The first four products—HETA Quality Control, HETA Tumor Detection, HETA Mitoses, and HETA Tumor Cellularity—automate assessments such as slide quality, tumor presence, mitotic count, and tumor cellularity on H&E whole-slide images. These tasks are traditionally performed visually, which is time-consuming and prone to inter-reader variability. Pathologists at leading academic medical centers estimate that 10-20% of molecular tests fail due to insufficient tumor tissue, leading to repeat biopsies and delays. HETA Clinical helps labs prioritize cases, reduce turnaround times, and ensure adequate tumor content before testing. All products are based on HETA, Aignostics' pan-cancer tissue analysis platform, which has demonstrated cell classification performance at or exceeding expert pathologists. Aignostics also announced early access to PathoSearch, a visual search engine for pathology cases. HETA Clinical will integrate with image management systems like Techcyte Fusion®AP.